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ABSTRACT
Purpose To test whether confocal laser scanning microscopy
(CLSM) can be used as an analytical tool to determine the drug
crystal size in a powder mixture or a crystalline solid dispersion.
Methods Crystals of the autofluorescent drug dipyridamole
were incorporated in a matrix of crystalline mannitol by
physical mixing or freeze-drying. Laser diffraction analysis and
dissolution testing were used to validate the particle size that
was found by CLSM.
Results The particle size of the pure drug as determined by
laser diffraction and CLSM were similar (D50 of approximately
22 μm). CLSM showed that the dipyridamole crystals in the
crystalline dispersion obtained by freeze-drying of less concen-
trated solutions were of sub-micron size (0.7 μm), whereas
the crystals obtained by freeze-drying of more concentrated
solutions were larger (1.3 μm). This trend in drug crystal size
was in agreement with the dissolution behavior of the tablets
prepared from these products.
Conclusion CLSM is a useful technique to determine the
particle size in a powder mixture. Furthermore, CLSM can be
used to determine the drug crystal size over a broad size
distribution. A limitation of the method is that the drug should
be autofluorescent.
KEY WORDS confocallaserscanningmiscroscopy.controlled
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INTRODUCTION
Many new drug candidates can be categorized as class II
drugs according to the Biopharmaceutics Classification
System (1). These drugs have a low aqueous solubility, but
once they are dissolved, they are easily absorbed over the
gastro-intestinal membrane (2,3). Since dissolution is the
rate limiting step for absorption for these drugs, the
bioavailability can be improved by increasing the dissolu-
tion rate (4). A strategy to increase the dissolution rate is the
application of drug nanocrystals (5–8). According to the
Ostwald-Freundlich equation (9) and the Noyes-Whitney
equation (10), the dissolution rate of drug nanocrystals is
increased due to an increased saturation concentration
around the small particles and due to an increased surface
to volume ratio.
Previously, we developed a novel bottom-up process to
produce such drug nanocrystals: controlled crystallization
during freeze-drying (CCDF) (11). Briefly, a drug and a
matrix material, dissolved in a mixture of tertiary butyl
alcohol (TBA) and water was rapidly frozen and then
freeze-dried. Freeze-drying was performed at a relatively
high temperature to allow both drug and matrix to
crystallize (12). By using this process, nanocrystalline
dispersions with improved dissolution behavior were
obtained.
Usually, methods such as dynamic light scattering (DLS)
and laser diffraction are used to measure the size of
nanoparticles. Disadvantages of these methods are that
when DLS is used, only the submicron particles can be
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DOI 10.1007/s11095-011-0484-8measured (13). And when laser diffraction is used, it is
difficult to apply the correct optimal parameters (14).
Nevertheless, these methods could provide accurate particle
size distributions of nanosuspensions. However, to be able
to measure nanoparticles with these methods, the particles
should be dispersed in a liquid. When top-down methods,
such as high pressure homogenization or wet ball milling,
are used, the obtained product is a nanosuspension.
However, when CCDF is used to prepare drug nano-
crystals, the particles should be dispersed in a liquid first. In
order to determine the size of the drug particles in the
matrix, the matrix material should dissolve in the liquid,
but the drug should not. Unfortunately, when the crystal-
line dispersions are dispersed in aqueous or non-aqueous
solvents, the drug particles can easily agglomerate or
dissolve rapidly (15). Agglomeration can be prevented by
the addition of surfactants. However, surfactants can cause
drugs to partially dissolve. This effect can lead to the
formation of sub-optimal crystal sizes (15,16).
If the particle size of the drug in the matrix could be
determined in solid state, these drawbacks would be
overcome. A frequently used method to distinguish between
different components in solid state is energy-dispersive X-
ray spectroscopy (EDX). For this method, it is required that
the different molecules in the mixture contain different
types of atoms and, preferably, that the deviating atom has
a high atomic mass. However, frequently, the atomic mass
or the concentration of the deviating atoms in the drug is too
low, or there are no deviating atoms at all. For example, in a
previous study (11), we used fenofibrate and mannitol as
model drug and matrix, respectively. The only atom type in
fenofibrate that is absent in mannitol is chloride. Since there
is only one chloride atom per molecule fenofibrate and the
atomic mass of chloride is low, EDX could not be used to
determine the drug crystal size.
Other methods that potentially could be used to
distinguish the drug from the matrix are Raman spectros-
copy or confocal laser scanning microscopy (CLSM). Both
techniques are used to determine the size distribution of a
drug in a mixture (17). At optimal conditions, the spatial
resolution of both techniques is approximately 0.25 μm
(18,19), which makes both techniques suitable to measure
particles in the sub-micron range. When Raman spectros-
copy is used, the characteristic peaks of both components
should not overlap; otherwise, discrimination of drug from
the matrix is impossible. On the other hand, to be able
to distinguish between the drug from the matrix when
CLSM is used, the drug of interest or the matrix
material should be autofluorescent. Since there are many
examples of autofluorescent drugs (e.g. dipyridamole,
nifedipine, tetracyclines, and acridines), CLSM could be
a useful method to determine the drug particle size.
The aim of this study was to focus on CLSM and to
test whether this technique can be used to determine the
drug crystal size in the solid state. In order to test this,
drug crystals of a poorly soluble and autofluorescent drug
were prepared by CCDF. Dipyridamole was selected as
model drug, because it can be categorized as BCS class
II drug (logP: 3.95 (20); aqueous solubility at neutral pH:
38 mg/L (21)), and it is autofluorescent due to its aromatic
ring system (22).
MATERIALS AND METHODS
Materials
Dipyridamole and TBA were obtained from Sigma-
Aldrich Chemie B.V. Zwijndrecht, The Netherlands.
Mannitol was obtained from Roquette (France). Fluorescent
TetraSpeck™ microspheres where obtained from Invitrogen
LifeScience.Demineralizedwaterwasusedinallexperiments.
Methods
Preparation of the Crystalline Dispersions
The controlled crystallized dispersions were prepared
according to the method described previously (11). Briefly,
two separate solutions of dipyridamole in TBA and
mannitol in water were prepared (for compositions see
Table I). Both solutions were heated to approximately 60°C
and mixed in a glass vial. Immediately after mixing, the
solutions were frozen by placing them on a pre-cooled
(−50°C) shelf of a freeze-dryer (Christ model Epsilon 2–4
lyophilizer, Breukelen, the Netherlands). This temperature
was maintained for 1.5 h, after which the temperature was
increased at a rate of 1°C/min to −25°C to allow the drug
and matrix to crystallize during a period of three ours.
Then, the samples were dried for 10 h at 0.220 mBar.
Finally, the temperature was gradually increased to room
temperature. The obtained powders were stored in a
dessicator over silica gel at room temperature for at least
one day before further processing.
Table I Composition of the Different Solutions Used to Prepare the
Controlled Crystallized Dispersions. In All Experiments, 1.2 mL Aquous
Solution was Mixed With 0.8 mL TBA Solution (i.e. ratio of 6/4)
Before lyophilization After lyophilization
Cdipyridamole/TBA (mg/ml) Cmannitol/water (mg/ml) Drug/matrix ratio
25.0 150 10/90
50.0 300 10/90
2568 de Waard et al.A physical mixture of dipyridamole and mannitol was
prepared using a spatula and mortar.
X-Ray Powder Diffraction
X-ray powder diffraction (XRPD) was performed using
CuKα radiation with a wavelength of 1.5405Å at 40 kV
and 40 mA from an X’Pert PRO MPD diffractometer
(PANalytical, Almelo, The Netherlands). The samples were
scanned from 4 to 60° 2θ with a step size of 0.008° and a
time per step of 35 s.
Scanning Electron Microscopy
SEM pictures were taken using a JEOL JSM 6301-F
microscope (JEOL, Japan). The samples were dispersed on
top of double-sided sticky carbon tape (Agar scientific,
Essex, United Kingdom) on metal disks and coated with a
thin layer of gold/palladium (Leica) in a Leica EM SCD
050 sputtering device. The acceleration voltage used was
4.0 kV.
Surface Brunauer, Emmet, and Teller-Isotherm Determination
Before analysis, the powder samples were filled into .25-inch
sample tubes and dried with nitrogen gas using a VacPrep
061 (Micromeritics, Norcross, U.S.A.). Thereafter, the
average surface area was determined using a Tristar 3000,
Micromeritics (Norcross, U.S.A.) BET.
Laser Diffraction
The particle size of the pure dipyridamole was determined
by laser diffraction. Small quantities dipyridamole were
dispersed by using a RODOS dispersing system (Sympatec
GmbH, Clausthal-Zellerfeld, Germany) at 1.0 bar. Then
the geometric particle size distribution was determined with
a a Sympatic HELOS compact model KA laser diffraction
apparatus (Sympatec GmbH, Clausthal-Zellerfeld, Germany).
A 100-mm lens was used, and calculations were based on the
Fraunhofer theory (23).
Confocal Laser Scanning Microscopy
CLSM images were obtained using a Leica TCS SP2
microscope (Leica, Mannheim, Germany) with an Argon
laser (excitation wavelength 458 nm). HCX PL APO CS
63x NA 1.4 (for the freeze-dried samples) and 40x NA 1.25
(for the physical mixture) oil objectives were used. Both
dipyridamole and mannitol were excited at 458 nm. To
obtain the fluorescent image of the dipyridamole crystals,
emission was measured at a wavelength of 482–551 nm. To
obtain a brightfield reflection image of complete powder,
scattered light was detected at a wavelength of 449–
471 nm. To increase the signal-to-noise ratio, the frame
average of six scans was used to produce one image. Since
the particle size of certified fluorescent beads was similar in
3-D and 2-D images (data not shown), 2-D images were
used to determine the particle size of drug in the
samples. Furthermore, since the optical slice thickness
(axial resolution) (calculated by Eq. 1,i nw h i c hdi st h e
optical slice thickness and an airyunit (p) of 1, a refractive
index (n) of 1.479 (oil), an excitation wavelength (λ)o f
458 nm, and a NA of 1.4 (63x lens) are used) is at least
400 nm and therefore larger than the expected radius of
the nanoparticles, the place where the imaging plane
intersects the particles does not influence the measured
particle size.
d ¼
p   n   lexc
NA2 ð1Þ
According to the Nyquist criterion (24) and the Huygens
(Huygens, SVI) specifications, the sampling density should
be a quarter of the resolution of the lens. Since the
numerical aperture of the 63x lens is 1.4, the theoretical
resolution of this lens is 196 nm. Similarly, the numerical
aperture of the 40x lens is 1.25, and the theoretical
resolution of this lens is 219 nm. Consequently the ideal
pixel size is 49 and 55 nm, respectively. However, since
most of the particles in the physical mixture are large, a
pixel size of approximately 183×183 nm was more suitable
and therefore used for images recorded with the 40x lens.
The pixel size of the images taken with the 63x lens was,
according to the Nyquist criterion, 50×50 nm. The digital
images were recorded in a 2,048×2,048 resolution.
Samples were prepared by using a spatula to spread the
powders onto a cover glass (glass thickness of 0.13-
0.17 mm, complying with the optical requirements of the
objectives). Only the cover glass was used during the CLSM
measurement.
Image Analysis
To increase the signal-to-noise ratio, the obtained fluores-
cent CLSM pictures were first deconvoluted using Classical
Maximum Likelihood Estimation algorithm and a mea-
sured point spread function (PSF) in the Huygens Profes-
sional 3.6 software from Scientific Volume Imaging. ImageJ
1.41n (National Institutes of Health, USA) was used to
change the deconvoluted images into binary images and to
measure the surface area of the particles. The threshold for
the grayscale to binary conversion was calculated by the
automatic thresholding function in ImageJ. To exclude the
counting of single pixels, originating from noise, only
CLSM as Method to Determine the Drug Crystal Size 2569particles with a surface area larger than an area of 4 pixels
were measured. Since the total surface area of particles at
the edge can not be determined, these particles were
excluded from analysis. The average surface area of each
individual particle was measured. Finally, the volume
median diameters were calculated by assuming that the
particles were spherical.
Validation
To validate whether this protocol can by used to measure
the particle size reliably, suspensions of certified fluorescent
beads of 0.18 μm (subresolution) 0.49 μm, 1.1 μm, and
4.0 μm were mounted on a cover glass. After the solvent
was removed by evaporation under atmospheric conditions,
the size of the beads was determined and analyzed according
to the protocol as described in the “Confocal Laser Scanning
Microscopy” and “Image Analysis” sections.
Tabletting
The obtained powders were compressed into 9-mm round
and flat tablets having a weight of 100 mg on a ESH
compaction apparatus (Hydro Mooi, Appingedam, The
Netherlands). The used compaction rate was 5 kN/s, and
the maximum compaction load was 5 kN. The tablets were
stored in a vacuum desiccator over silica gel at room
temperature for at least one day before further processing.
Dissolution
The dissolution behavior of dipyridamole from the tablets
was determined by using a USP dissolution apparatus II
(Sotax AT 7, Basel, Switzerland). As dissolution medium
1 L of a pH 6.8 phosphate buffer with 0.05% w/v sodium
Table II Particle Size of Certified Fluorescent Beads Measured and
Analyzed According to the Protocol. The Given Measured Bead Size is the
Mean ± Standard Deviation of Five Samples
Specified beads size (μm) Measured bead size (μm)
0.49 0.45±0.12
1.1 1.2±0.1
4.0 4.2±0.4
Fig. 1 X-ray diffraction patterns of δ-mannitol, dipyridamole as received,
and the dispersions that were prepared freeze-drying from solutions
containing 25.0 and 50.0 mg/mL dipyridamole in TBA. In the patterns of
the solid dispersions, the major dipyridamole peak at 8.1° 2θ is clearly
visible, but also minor dipyridamole peaks at 8.9, 10.3, 18.8, 20.9, 23.5,
and26.1°2θwerefound.Bothdispersionscontained10%w/wdipyridamole
in mannitol.
Fig. 2 SEM pictures of two controlled crystallized dispersions. Both
contain 10% w/w dipyridamole in mannitol, but one was prepared from a
solution containing 25.0 mg/mL dipyridamole in TBA (top), while the
other was prepared from a solution containing 50.0 mg/mL dipyridamole
in TBA (bottom). Both pictures have a magnification of 5000x.
2570 de Waard et al.dodecyl sulphate at a temperature of 37°C was used. The
paddle speed was set at 100 rpm. The concentration of
dipyridamolewasmeasuredspectrophotometrically(Evolution
300 UV–VIS spectrophotometer, Thermo Fisher Scientific,
Madison, U.S.A.) at a wavelength of 285 nm.
RESULTS
Validation
To validate the image acquisition and analysis protocols,
the size of certified fluorescent beads was determined. First,
subresolution beads (175 nm) were measured. The detected
resolution was close to the theoretical resolution of the
microscope. Second, beads of 0.5, 1.0, and 4.0 μm were
measured. The results found for the certified beads were
close to the specified size of these beads (Table II), thus
indicating that the described protocol can be used to
measure the particle size reliably.
Physicochemical Characterization of the Dispersions
To determine the crystallinity of the obtained dispersions,
XRPD was used. Differential scanning calorimetry, which
is a common technique to quantify crystallinity, could not
be used because the melting point of dipyridamole and
mannitol are almost equal to each other (163°C and 166°C
Fig. 3 A comparison between the particle size obtained by CLSM (black
bars) and by laser diffraction (grey bars). The particle size obtained by
CLSM is the mean ± standard deviation of three samples. From each
sample, 50 images were acquired; per sample, more than 2,000 particles
were measured. The particle size obtained by laser diffraction is the
mean ± standard deviation of three measurements.
Fig. 4 Examples of a merged image of the brightfield reflection image and fluorescent dipyridamole images (left), fluorescent images (middle), and binary
images (right) of the controlled crystallized dispersions obtained from the solution containing 25 mg/mL (top) and 50 mg/mL (bottom) dipyridamole in TBA.
Both controlled crystallized dispersions contain 10% w/w dipyridamole in mannitol.
CLSM as Method to Determine the Drug Crystal Size 2571respectively (21,25)). Consequently, the peaks in the
thermogram overlap; therefore, the degree of crystallinity
could not be determined. However, the XRPD patterns
clearlyrevealedthemajordipyridamolepeakat8.1°2θ,ot he r
smaller dipyridamole peaks, and peaks corresponding to δ-
mannitol. This indicates that the obtained dispersions
consisted of crystalline dipyridamole and δ-mannitol (Fig. 1).
SEM analysis of CCDF-generated nanoparticles
revealed increased particle sizes with increasing concen-
trations of dipyridamole in TBA and mannitol in water
(Fig. 2). The BET results showed that the particles obtained
from the less concentrated solutions had a larger surface
area (4.6 m
2/g) than the particles obtained from the more
concentrated solutions (3.7 m
2/g). These results agree with
the SEM findings and are an indication that the particle
size is smaller when the samples are freeze-dried from less
concentrated solutions.
Comparison Between Laser Diffraction and CLSM
First, it was validated whether CLSM can be used to
determine the particle size of the autofluorescent drug while
the drug is mixed with a second component. Thereto the
pure drug crystal size as determined by laser diffraction was
compared with the dipyridamole crystal size in a physical
mixture as determined by CLSM. The fluorescent dipyr-
idamole signal and the reflected light could easily be
separated from each other by CLSM (data not shown). By
CLSM analysis, the particle size of the pure drug was found
to be similar to the size of the unprocessed drug in the
physical mixture (Fig. 3). The most frequently used value to
indicate the particle size, the D50 value, was found to be
21.7±0.5 μm (mean ± standard deviation of 3 samples)
and 23.9±2.8 μm (mean ± standard deviation of 3 sets of
50images;eachsetconsistedof3,251–4,826particles)bylaser
diffractionandCLSM,respectively,fortheunprocesseddrug.
These results indicate that CLSM in combination with the
image analysis can be used to determine the particle size of an
autofluorescent drug, even though it is mixed with a second
component.
Particle Size Analysis and Dissolution
The two previously described dispersions were used to test
whether CLSM can also be used as an analytical tool to
determine the size of fluorescent drug crystals in solid
dispersions. Also in these samples, the dipyridamole and
mannitol could be clearly distinguished from each other by
CLSM, and the fluorescent dipyridamole signal could be
separated from the mannitol signal (Fig. 4). After deconvo-
lution, the grey-scale images were converted into binary
images. The volume-based particle size distribution was
calculated from the binary images.
The calculated particle size distributions do not only
show a clear difference in particle size between the physical
mixture and the crystallized dispersions, but also between
the two crystallized dispersions (Fig. 5a). The D50 of
dipyridamole in the physical mixture was found to be
22 μm, while the size was 0.7 and 1.3 μm for the crystals in
the dispersions prepared from the less concentrated and
more concentrated solutions, respectively.
Although dissolution experiments can not be used to
quantify the drug crystal size, differences between drug
crystal sizes are reflected in differences in dissolution rate.
The dissolution experiments showed that the dissolution
rate of dipyridamole was higher from the controlled
crystallized dispersions than from the physical mixture
(Fig. 5b). Furthermore, it can be seen that the dissolution
Fig. 5 (a) Particle size distribution of the crystalline dispersions obtained
from the 25 mg/mL (light grey) and 50 mg/mL (dark grey) dipyridamole in
TBA solution and the physical mixture (black). (b) Dissolution profiles of
dipyridamole from tablets composed of the physical mixture (filled circle)
and controlled crystallized dispersions. The dispersions were prepared
from a solution containing 25 mg/mL (white circle) and 50 mg/mL (filled
circle) dipyridamole in TBA. The D50-values in the figure are the values as
determined in (a). All tablets contained 10% w/w dipyridamole (n=3–6;
mean ± standard deviation).
2572 de Waard et al.rate was faster when the crystalline dispersion was prepared
from the less concentrated solutions. Since all samples were
crystalline, a higher dissolution rate indicates smaller
crystals. Therefore, it can be concluded that the CLSM
findings, which show that the dipyridamole crystals from
the less concentrated solutions are the smallest, are in
agreement with the results of the dissolution experiments.
DISCUSSION
In this study, we showed that CLSM, in combination with a
two-step image analysis process, can be used as a tool to
determine the particle size of autofluorescent drug crystals in
the solid state. To validate this, first the pure dipyridamole
crystal size was determined by laser diffraction analysis. The
found crystal size was compared to the size of the same drug
crystals physically mixed with mannitol as determined by
CLSM. Both methods showed a similar particle size distribu-
tion, indicating that the combination of CLSM and image
analysis can be used to determine the crystal size of
dipyridamole that is mixed with a second component.
In a previous study (11), we developed CCDF as a novel
process to prepare drug nanocrystals. In another study (12),
we showed that the size of the drug crystals was limited to
the size of the interstitial spaces between the frozen solvent
crystals. We hypothesized in this study that when less
concentrated solutions are freeze-dried, more solvent
crystals and therefore smaller interstitial spaces are formed,
and consequently smaller drug crystals will be formed.
The results of the BET measurements suggested that the
particles obtained from the less concentrated solutions were
indeed smaller than the particles obtained from the more
concentrated solutions. Furthermore, the SEM pictures
suggested that the particles obtained from the less concen-
trated solutions were of sub-micron size, while the particles
from the more concentrated solutions were larger than a
micrometer. However, both methods can not distinguish
the drug from the matrix.
The CLSM analysis, on the other hand, can distinguish
between drug and matrix, and it can be used to quantify
the drug crystal size in the crystalline dispersion. It showed
that the crystals in the dispersion prepared from the less
concentrated solution were of sub-micron size, whereas the
crystals in the dispersion prepared from the more concen-
trated solution were approximately 1.3 μm.
This trend in drug crystal size was in agreement with the
dissolution behavior of the tablets prepared from the
physical mixture and the freeze-dried products. Since the
pure drug, but also both freeze-dried dispersions, are all
crystalline, differences in dissolution rate can be ascribed to
differences in drug crystal size. Therefore, the dissolution tests
showed that the dipyridamole crystals obtained from the less
concentrated solutions were indeed smaller than the dipyr-
idamole crystals from the more concentrated solutions.
These results indicate that CLSM is a useful technique
to determine the drug crystal size in a powder mixture. The
fact that in the crystallized dispersions sub-micron-sized
particles were analyzed and in the physical mixture
particles of several tens of micrometers indicates that the
CLSM method can be used to measure the particle size
over a size range covering several orders of magnitude.
Furthermore, the particle size of only one of the compo-
nents in a mixture or dispersion, instead of that of the
combination, can be determined. A limitation of the
method is that it is limited to autofluorescent drugs.
However, when the drug of interest is autofluorescent,
CLSM could be a valuable tool.
CONCLUSION
In conclusion, CLSM can be used to determine the drug
crystal size of an autofluorescent drug in a powder mixture
independent from the mode of incorporation. Advantages
are that it can be used to determine the drug crystal size in
solid state and that the size of one component in a mixture
or dispersion can be determined. Furthermore, CLSM can
be used to determine the size of crystals of several hundreds
of nanometers to tens of micrometers. A limitation is that
this method can only be applied to autofluorescent
compounds. In addition to this, we showed that the drug
crystal size in the crystalline dispersion, prepared by CCDF,
could be controlled by the concentration of drug and
matrix in the initial solution.
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